Transcription of HIGHLIGHTS OF PRESCRIBING INFORMATION ——— …
{{id}} {{{paragraph}}}
Example: bachelor of science
HIGHLIGHTS OF PRESCRIBING INFORMATION ——— …
HIGHLIGHTS OF PRESCRIBING INFORMATION Hyper- or hypoglycemia with changes in insulin regimen: Carry out under close medical These HIGHLIGHTS do not include all the INFORMATION needed to use TRESIBA safely supervision and increase frequency of blood glucose monitoring ( ). and effectively. See full PRESCRIBING INFORMATION for TRESIBA . Hypoglycemia: May be life-threatening. Increase monitoring with changes to: insulin dosage, TRESIBA (insulin degludec injection), for subcutaneous use co-administered glucose lowering medications, meal pattern, physical activity; and in patients Initial Approval: 2015 with renal impairment or hepatic impairment or hypoglycemia unawareness ( , , ). Hypoglycemia due to medication errors: Accidental mix-ups between insulin products can occur. RECENT MAJOR CHANGES Instruct patients to check insulin labels before injection. DO NOT transfer TRESIBA into a Dosage and Administration (2) 03/2018 syringe for administration as overdosage and severe hypoglycemia can result ( ).
needed to use TRESIBA® safely and effectively. See ... octreotide), and sulfonamide antibiotics (7). • Drugs that may decrease the blood glucose lowering effect: atypical antipsychotics, corticosteroids, danazol, diuretics, ... Patients using TRESIBA ...
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: